EUVIMEDEUVIMED entdecken
Open Access

Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda

J Sung, A Musinguzi, J L Kadota, Y Baik, J Nabunje, F Welishe, O Bishop, C A Berger, A Katahoire, A Nakitende, J Nakimuli, L Akello und 9 weitere

The International Journal of Tuberculosis and Lung Disease · 2023

DOI: 10.5588/ijtld.22.0679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2023. Verfasst von J Sung und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Tuberculosis, Latent Tuberculosis, Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Twelve weeks of weekly isoniazid and rifapentine (3HP) prevents TB disease among people with HIV (PWH), but the costs to people of taking TB preventive treatment is not well described. METHODS: We surveyed PWH who initiated 3HP at a large urban HIV/AIDS clinic in Kampala, Uganda, as part of a larger trial. We estimated the cost of one 3HP visit from the patient perspective, including both out-of-pocket costs and estimated lost wages. Costs were reported in 2021 Ugandan shillings (UGX) and US dollars (USD; USD1 = UGX3,587) RESULTS: The survey included 1,655 PWH. The median participant cost of one clinic visit was UGX19,200 (USD5.36), or 38.5% of the median weekly income. Per visit, the cost of transportation was the largest component (median: UGX10,000/USD2.79), followed by lost income (median: UGX4,200/USD1.16) and food (median: UGX2,000/USD0.56). Men reported greater income loss than women (median: UGX6,400/USD1.79 vs. UGX3,300/USD0.93), and participants who lived further than a 30-minute drive to the clinic had higher transportation costs than others (median: UGX14,000/USD3.90 vs. UGX8,000/USD2.23). CONCLUSION: Patient-level costs to receive 3HP accounted for over one-third of weekly income. Patient-centered approaches to averting or defraying these costs are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisLatent TuberculosisAcquired Immunodeficiency SyndromeMaleHumansFemaleIsoniazidAntitubercular AgentsUgandaDrug Therapy, CombinationRifampin

Substanzen

IsoniazidAntitubercular AgentsrifapentineRifampin

Autor:innen und Institutionen

  • Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Division of Pulmonary and Critical Care Medicine and Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
  • Child Health and Development Centre, Makerere University College of Health Sciences, Kampala, Uganda.
  • Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Sung, J., Musinguzi, A., Kadota, J. L., Baik, Y., Nabunje, J., Welishe, F., Bishop, O., Berger, C. A., Katahoire, A., Nakitende, A., Nakimuli, J., Akello, L., Kasidi, J. R., Kunihira Tinka, L., Kamya, M. R., Sohn, H., Kiwanuka, N., Katamba, A., Cattamanchi, A., …, & Semitala, F. C. (2023). Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.22.0679

Vancouver

Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, et al. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda. The International Journal of Tuberculosis and Lung Disease. 2023. doi:10.5588/ijtld.22.0679

BibTeX
@article{Sung2023,
  author = {Sung, J and Musinguzi, A and Kadota, J L and Baik, Y and Nabunje, J and Welishe, F and Bishop, O and Berger, C A and Katahoire, A and Nakitende, A and Nakimuli, J and Akello, L and Kasidi, J R and Kunihira Tinka, L and Kamya, M R and Sohn, H and Kiwanuka, N and Katamba, A and Cattamanchi, A and Dowdy, D W and Semitala, F C},
  title = {Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2023},
  doi = {10.5588/ijtld.22.0679}
}
Kostenlos starten →